Omadacycline as a promising tetracycline alternative for treating community-acquired bacterial pneumonia: Indian experience

This is the authors' abstract. We don't add key points for this paper.

Omadacycline , a novel tetracycline that has been approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSIs). In the present study, we evaluated the in-vitro activity of omadacycline against bacterial pathogens causing CABP. Non-duplicate isolates of methicillin susceptible Staphylococcus aureus (MSSA) (n = 105), methicillin resistant S . aureus (MRSA) (n = 102), Streptococcus pneumoniae (n = 100) and Moraxella catarrhalis (n = 102) were included. The minimum inhibitory concentration of omadacycline and other comparators were determined using the broth microdilution method. Overall, omadacycline potently inhibited MSSA (MIC 90 0.25 mg/L), MRSA (MIC 90 0.5 mg/L), S. pneumoniae (MIC 90 0.06 mg/L) and M. catarrhalis (MIC 90 0.12 mg/L) isolates. This finding reiterates that omadacycline could be a potential treatment alternative for treating severe CABP.